Amrutanjan Health Care Limited (AMRUTANJAN.BO)
INR 634.7
(-0.24%)
INR 634.7
(-0.24%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 682.53 Million INR | -12.09% |
| 2022 | 590.79 Million INR | -37.87% |
| 2021 | 946.98 Million INR | 9.85% |
| 2020 | 861.66 Million INR | 127.41% |
| 2019 | 391.52 Million INR | -0.65% |
| 2018 | 385.29 Million INR | 11.82% |
| 2017 | 361.72 Million INR | -10.72% |
| 2016 | 373.98 Million INR | 4.64% |
| 2015 | 371.78 Million INR | 30.5% |
| 2014 | 280.62 Million INR | 9.15% |
| 2013 | 247.82 Million INR | 37.81% |
| 2012 | 187.95 Million INR | -18.86% |
| 2011 | 229.74 Million INR | 28.24% |
| 2010 | 179.15 Million INR | -1.78% |
| 2009 | 201.19 Million INR | -7.03% |
| 2008 | 192.73 Million INR | 69.5% |
| 2007 | 112.89 Million INR | -29.41% |
| 2006 | 161.99 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 35.48 Million INR | -62.24% |
| 2023 Q3 | 215.73 Million INR | 99.95% |
| 2023 Q1 | 108.45 Million INR | -39.06% |
| 2023 FY | - INR | -12.09% |
| 2023 Q2 | 107.89 Million INR | -0.52% |
| 2023 Q4 | 162.36 Million INR | -24.74% |
| 2022 Q4 | 177.98 Million INR | 12.41% |
| 2022 Q1 | 63.41 Million INR | -70.52% |
| 2022 Q2 | 189.6 Million INR | 198.98% |
| 2022 FY | - INR | -37.87% |
| 2022 Q3 | 158.33 Million INR | -16.49% |
| 2021 Q4 | 215.13 Million INR | -25.36% |
| 2021 FY | - INR | 9.85% |
| 2021 Q1 | 172.91 Million INR | 14.75% |
| 2021 Q2 | 272.29 Million INR | 57.48% |
| 2021 Q3 | 288.22 Million INR | 5.85% |
| 2020 Q1 | 96.54 Million INR | -17.71% |
| 2020 Q4 | 150.68 Million INR | -48.09% |
| 2020 Q3 | 290.3 Million INR | -10.18% |
| 2020 Q2 | 323.21 Million INR | 234.79% |
| 2020 FY | - INR | 127.41% |
| 2019 Q2 | 134.39 Million INR | 320090.48% |
| 2019 Q4 | 117.31 Million INR | -15.4% |
| 2019 Q3 | 138.67 Million INR | 3.18% |
| 2019 Q1 | -42 Thousand INR | -100.02% |
| 2019 FY | - INR | -0.65% |
| 2018 Q1 | -13.08 Million INR | -111.53% |
| 2018 FY | - INR | 11.82% |
| 2018 Q4 | 207.63 Million INR | 148.0% |
| 2018 Q3 | 83.72 Million INR | -18.7% |
| 2018 Q2 | 102.97 Million INR | 887.23% |
| 2017 Q2 | 149.75 Million INR | 1766.58% |
| 2017 FY | - INR | -10.72% |
| 2017 Q3 | 86.82 Million INR | -42.02% |
| 2017 Q4 | 113.49 Million INR | 30.71% |
| 2017 Q1 | -8.98 Million INR | -111.35% |
| 2016 Q3 | 92.83 Million INR | -22.56% |
| 2016 Q2 | 119.87 Million INR | 0.0% |
| 2016 FY | - INR | 4.64% |
| 2016 Q4 | 79.2 Million INR | -14.69% |
| 2015 FY | - INR | 30.5% |
| 2014 FY | - INR | 9.15% |
| 2013 FY | - INR | 37.81% |
| 2012 Q2 | 57.67 Million INR | 355.2% |
| 2012 Q3 | 63.02 Million INR | 9.27% |
| 2012 Q4 | 83.42 Million INR | 32.36% |
| 2012 FY | - INR | -18.86% |
| 2012 Q1 | 12.67 Million INR | 0.0% |
| 2011 FY | - INR | 28.24% |
| 2010 FY | - INR | -1.78% |
| 2009 FY | - INR | -7.03% |
| 2008 FY | - INR | 69.5% |
| 2007 FY | - INR | -29.41% |
| 2006 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.507% |
| NATCO Pharma Limited | 18.79 Billion INR | 96.369% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 85.407% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -58.628% |
| Achyut Healthcare Limited | 524 Thousand INR | -130155.344% |
| Ajanta Pharma Limited | 12.56 Billion INR | 94.568% |
| Alkem Laboratories Limited | 24.19 Billion INR | 97.179% |
| Alpa Laboratories Limited | 86.12 Million INR | -692.479% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 92.903% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 71.04% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 98.895% |
| Bajaj HealthCare Limited | 444.51 Million INR | -53.546% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 53.852% |
| Brooks Laboratories Limited | 41.72 Million INR | -1535.683% |
| Divi's Laboratories Limited | 25.43 Billion INR | 97.316% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 99.227% |
| Eris Lifesciences Limited | 6.98 Billion INR | 90.231% |
| FDC Limited | 4.4 Billion INR | 84.494% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 93.983% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 90.055% |
| Granules India Limited | 8.6 Billion INR | 92.067% |
| Gufic Biosciences Limited | 1.48 Billion INR | 53.898% |
| Hester Biosciences Limited | 539.47 Million INR | -26.52% |
| Indoco Remedies Limited | 2.64 Billion INR | 74.215% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 90.053% |
| Ipca Laboratories Limited | 13.29 Billion INR | 94.868% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -111.012% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 925.049% |
| Lasa Supergenerics Limited | -65.08 Million INR | 1148.768% |
| Laurus Labs Limited | 8 Billion INR | 91.475% |
| Lupin Limited | 36.96 Billion INR | 98.154% |
| Mankind Pharma Limited | 28.09 Billion INR | 97.571% |
| Medicamen Biotech Limited | 245.66 Million INR | -177.838% |
| Medico Remedies Limited | 150.37 Million INR | -353.882% |
| Megasoft Limited | 284.73 Million INR | -139.713% |
| Piramal Pharma Limited | 13.05 Billion INR | 94.772% |
| RPG Life Sciences Limited | 1.28 Billion INR | 46.739% |
| Sigachi Industries Limited | 883.39 Million INR | 22.737% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 118.292% |
| Unichem Laboratories Limited | 742.35 Million INR | 8.058% |
| Wanbury Limited | 985.49 Million INR | 30.741% |
| Windlas Biotech Limited | 781.72 Million INR | 12.688% |
| ZIM Laboratories Limited | 462.09 Million INR | -47.704% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 98.786% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 77.357% |
| Bal Pharma Limited | 345.59 Million INR | -97.498% |
| Strides Pharma Science Limited | 3.76 Billion INR | 81.87% |
| Venus Remedies Limited | 711.8 Million INR | 4.111% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 82.541% |
| Nectar Lifesciences Limited | 1.56 Billion INR | 56.354% |
| Shilpa Medicare Limited | 2.58 Billion INR | 73.627% |
| Aarti Drugs Limited | 3.24 Billion INR | 78.99% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 73.815% |
| Suven Life Sciences Limited | -992.78 Million INR | 168.75% |
| Ind-Swift Limited | 1.06 Billion INR | 35.916% |
| Valiant Laboratories Limited | 12.73 Million INR | -5257.862% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 92.688% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 124.187% |
| Themis Medicare Limited | 562.6 Million INR | -21.317% |
| Hikal Limited | 2.69 Billion INR | 74.648% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 98.05% |
| Sequent Scientific Limited | 549.8 Million INR | -24.143% |
| Novartis India Limited | 1.26 Billion INR | 46.227% |
| Wockhardt Limited | 1.08 Billion INR | 36.802% |
| Jubilant Pharmova Limited | 8 Billion INR | 91.475% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -5125.371% |
| Neuland Laboratories Limited | 4.74 Billion INR | 85.625% |
| Morepen Laboratories Limited | 1.72 Billion INR | 60.454% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -137.466% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -290.142% |